NCT00094822CompletedNot Applicable
Pegfilgrastim Given Same Day as or Day After Carboplatin and Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Amgen
- Enrollment
- 90
- Primary Endpoint
- incidence of infection
Study Overview
Brief Summary
The purpose of this research study is to evaluate the safety and effectiveness of Neulasta® (pegfilgrastim) in reducing infection when given on the same day versus one day after the completion of chemotherapy (docetaxel and carboplatin) in patients with advanced or metastatic non-small cell lung cancer (NSCLC). This study is considered to be "investigational" because previous studies with Neulasta® used next day dosing and not same day dosing.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
incidence of infection
Time Frame: during treatment
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Completed
Phase 2
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast CancerStage I Breast CancerStage II Breast CancerBreast CancerNCT00146562Harold J. Burstein, MD, PhD135
Completed
Phase 1
Neulasta in Type 1 DiabetesType 1 DiabetesNCT00662519University of Florida21
Completed
Phase 4
An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)Non-Hodgkin's LymphomaNCT02782845Hoffmann-La Roche53
Completed
Phase 4
Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast CancerBreast CancerNCT03511378Lupin Ltd.138
Completed
Phase 2
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)FeverNeutropeniaBreast CancerNCT00115414Amgen